Circadin, now called Vigisom

Circadin, now called Vigisom

Supplied by Aspen New Zealand
1 minute to Read
Vigisom launch Hosted Content
The same, in all but name

From 1st November 2021, the prolonged release melatonin, Circadin, will go by the new name, Vigisom.

It is important to know that this is a brand name change only. Vigisom is made by the same manufacturer, with the same active and inactive ingredients and works in exactly the same way – only the name (and packaging) will be different.

Not something to lose sleep over

Naturally, for some of your patients who have used Circadin in the past, this has the potential to cause anxiety if they feel they are getting a different medication. For this reason, it will be very important to reassure them and explain that the medication itself is exactly the same.

To help with this, Aspen New Zealand have a supply of resources for use at point of prescribing and dispensing.

One other difference – Vigisom is more affordable

As well as helping New Zealanders get the sleep they need, they also can sleep sound in the knowledge that Vigisom is not only effective and non-addictive, but also offers improved affordability.

So along with a new name, Vigisom comes at a lower cost (than Circadin) for your unfunded patients.

Want to know more about Vigisom?

If you would like to know more about the Circadin to Vigisom name change, the resources available or if you have questions about pricing and ordering, please contact your local Aspen representative or email us:

Circadin® /Vigisom® (melatonin) Prolonged Release tablets 2mg. INDICATION: Monotherapy for the short term treatment of primary insomnia characterized by poor quality of sleep in patients aged 55 or over. CONTRAINDICATIONS: Known hypersensitivity to any ingredient in the product. PRECAUTIONS: renal insufficiency, use in the elderly. Not recommended in patients with autoimmune diseases, hepatic impairment, galactose intolerance, LAPP lactase deficiency, glucose-galactose malabsorption, children <18 years, pregnancy (Category B3) and lactation. Patients should avoid engaging in hazardous activities (eg driving/operating machinery) after taking Circadin/Vigisom. COMMON SIDE EFFECTS: Headache, nasopharyngitis, back pain and arthralgia. DOSAGE AND ADMINISTRATION: One tablet daily after food 1-2 hours before bedtime. Treat for up to thirteen weeks. Circadin/Vigisom is an unfunded medicine. Prescription Medicine except when supplied by a Registered Pharmacist. Normal Doctors fees and Pharmacy Charges apply. Special Authority funding criteria may apply. Circadin/Vigisom is listed on the HML. Please review Data Sheet before prescribing/supplying, available at Circadin®/Vigisom® is a registered trademark of Neurim Pharmaceuticals Limited used under licence by Aspen New Zealand C/O Pharmacy Retailing (NZ) Ltd, Auckland. TAPS BG1594-SEP21. INSIGHT 11045.